Close Menu

NEW YORK – NuProbe and Qiagen have entered into a strategic collaboration to develop next-generation sequencing-based cancer liquid biopsy tests, the firms announced Monday.

Under the terms of their agreement, NuProbe and Qiagen will explore integration of their amplicon-based target enrichment technologies — NuProbe's blocker displacement amplification (BDA) and Qiagen's single primer extension technology — to analyze DNA mutations with low variant allele fractions.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.